Genzyme Sales Of Myozyme Doubled In Fourth Quarter 2007
This article was originally published in The Pink Sheet Daily
Executive Summary
Enzyme replacement therapy for Pompe disease recorded $62 million in sales in the quarter, representing the most rapid growth of any of the firm’s lysosomal products.
You may also be interested in...
Pending Approvals Hold Major Implications For Myozyme Growth
Genzyme reports increasing sales for Pompe disease drug, but upcoming EU and FDA decisions could spur or stifle product’s growth.
Pending Approvals Hold Major Implications For Myozyme Growth
Genzyme reports increasing sales for Pompe disease drug, but upcoming EU and FDA decisions could spur or stifle product’s growth.
Icahn Leaves Pool, Genzyme Shareholder No More
Cambridge neighbor Biogen Idec, meanwhile, girds for a power struggle at its May annual meeting.